ccumulating evidence suggests that unstable angina frequently results from platelet aggregation or thrombus formation at the site of fissured atheromatous plaques that may occur even at sites without significant preexisting coronary arterial narrowing.1,2 Studies in animals have shown that the intracoronary activation of platelets may contribute to or cause myocardial ischemia both by causing mechanical obstruction of the arterial lumen and by releasing potent segments to intracoronary infusions of serotonin in patients with differing clinical presentations of coronary atherosclerosis and in control patients with normal coronary arteries.
Methods Patients
We studied 25 patients admitted for routine cardiac catheterization. The study protocol was approved by the Research Ethics Committee of the University of Lille. Informed consent for the discontinuation of therapy and the intracoronary administration of serotonin and ketanserin was obtained from all patients. Regular antianginal medication was discontinued at least 24 hours before catheterization. All the patients were taking aspirin 100-300 mg daily, which was continued. Patients were allowed to use sublingual nitroglycerin as needed, but no study was performed within 3 hours of its administration. No premedication was given.
Drugs
Serotonin creatinine sulfate was prepared for human use by the Hammersmith Hospital Pharmacy (London) and stored at -20°C in ampules containing 5 ml of 10 2 mol/l solution until just before use. The stock solution was diluted with normal saline (0.9%) to achieve final infused concentrations of 10`6 to 10-4 mol/l. Ketanserin (as ketanserin tartrate, Serapress) was a gift from Formenti S.r.l. (Milan, Italy). Ampules containing 10 mg of ketanserin were diluted in saline to a concentration of 0.375 mg/ml.
Invasive Protocol
Two ECG leads were monitored continuously throughout the study. Femoral arterial pressure, heart rate, and two ECG leads were recorded during the last 30 seconds of the infusions. After the diagnostic study, an optimal view was chosen to visualize the coronary artery to be studied, and the position of the camera subsequently remained unchanged. Heparin was not routinely administered. All infusions were administered through 8F Judkins catheters at room temperature at a rate of 1 ml/min with use of a syringe pump (Perfusor, Braun-Melsungen). We have previously shown that intracoronary infusion of saline or injection of contrast medium is not associated with a significant change in coronary diameter.14 The patients therefore received a single 2-minute infusion of vehicle solution (0.9% saline) followed by 2-minute infusions of serotonin creatinine sulfate or ketanserin (0.375 mg/ml) according to the protocols outlined below. Finally, an intracoronary bolus dose of isosorbide dinitrate (ISDN) (2 mg in 2 ml of saline) was administered. Angiography was performed at baseline and after each infusion after the hand injection of 6-8 ml of contrast (Omnipaque, Nycomed). Before each angiogram, the catheter was emptied to avoid the effects of bolus administration of serotonin.
Study Protocols
Reproducibility of vasoconstriction. Tachyphylaxis to the effects of serotonin is frequently observed in animal models; therefore, we initially compared the degree of same concentration of serotonin. We studied seven patients (four men and three women) with a mean+SEM age of 50.0±+9.8 years who had angiographic evidence of atherosclerosis. Four 
Group 3, Variant Angina
We studied three patients (two men and one woman) with a mean age of 50.7 years. All presented with spontaneous, predominantly early-morning angina and had negative results on exercise testing. Provocation testing with ergonovine caused angina associated with a marked shift of the ST segment (elevation in leads V1 through V4 in patient 1, depression in leads V5 and V6 in patients 2 and 3). All three patients had isolated vasoconstriction induced by repeated infusion of the 
Quantitative Coronary Angiography
The coronary arteriograms were analyzed with use of the CAESAR (Computer Assisted Evaluation of Stenosis And Restenosis) System, a computerized automatic analysis system. The 35-mm cine film was projected with a 35AX projector (Tagarno, Denmark), and the cine frame selected for analysis was scanned with a highresolution (matrix 1,024x 1,024 pixels) CCD video camera. The signal produced by the video camera was digitized and displayed on a video monitor. Regions of interest were chosen in the vessel, and a center line was manually traced with a light pencil. The contours of the vessel were then automatically detected on the basis of the weighted sum of first and second derivative functions applied to the digitized brightness information. The diameter of the coronary catheter was used to convert the imaging data from pixels to millimeters. We had previously determined the accuracy (defined as the signed difference between the measured and true value) and the precision (defined as the standard deviation of these differences) of the CAESAR system in a study analyzing cine films of Plexiglas blocks containing precision-drilled models of coronary arteries filled with contrast medium. The accuracy was 0.07 mm, and the precision was 0.14 mm. In a separate study, we analyzed the intraobserver and interobserver variability of the CAESAR system in our institution. Ninety arterial segments from patients undergoing percutaneous transluminal coronary angioplasty were analyzed by two independent observers and reanalyzed at a remote time. The mean intraobserver variation, expressed as the standard error of the estimate (SEE), was 0.12 mm. The interobserver variation (SEE) was 0.10 mm.
To quantify the effects of interventions, arterial segments were chosen on end-diastolic frames from the proximal and distal portions of the infused artery as defined according to the classification of the American Heart Association Committee Report's and analyzed at baseline and after each intervention. For left coronary infusions, segments from the proximal (segment 6) and distal (segment 8) left anterior descending artery were chosen; for right coronary infusions, segments from the proximal (segment 1) and distal (segment 3) right coronary artery were chosen. Because the response to serotonin was nonuniform along the vessel, we took the measurements in the segments in which the greatest change had occurred during infusion of the peak concentration of serotonin before ketanserin. The response of discrete stenotic segments (group 3) was studied by 
Results
There were no significant changes in heart rate or systolic arterial blood pressure associated with the intracoronary infusion of saline, ketanserin, or serotonin.
The changes observed in the vessel segments we studied are detailed in Tables 1 and 2 
Control Patients
In the control patients, serotonin caused significant constriction in distal epicardial vessels that was signifi- cantly inhibited by ketanserin. Vasodilation did not occur after the infusion of ketanserin or after the subsequent infusion of serotonin.
These results are consistent with the results of studies in vitro9 that suggest that serotonin has a direct vasoconstrictor effect on normal human epicardial vessels. Isolated human coronary vessels, even when preconstricted, do not relax when exposed to serotonin or to 5-carboxamidotryptamine, a selective S,-like receptor agonist946; however, the constrictor response of vessels studied at basal tension is markedly enhanced by endothelial removal, which suggests that normal endothelium attenuates a direct constrictor effect on smooth muscle.9
The results of experimental studies with vasoactive agents in vitro cannot necessarily be extrapolated to the intact coronary circulation. With intraluminal infusion, the first interaction is with the endothelium, whereas in isolated rings, effects on the endothelium and on vascular smooth muscle occur simultaneously; furthermore, in vivo, other factors such as an effect on coronary blood flow may independently affect epicardial diameter.17
However, epicardial constriction also occurs when serotonin is directly infused into the coronary circulation of the dog, which demonstrates the existence of a direct epicardial constrictor effect in vivo.1819 In fact, epicardial constriction occurs despite a concomitant increase in coronary blood flow, suggesting that serotonin has opposite effects on epicardial and resistance vessels. This has been directly demonstrated by a recent study that showed that serotonin constricts feline epicardial vessels >90-Mm diameter but dilates arterioles with a smaller caliber. 20 Golino et a18 recently showed that intracoronary infusion of serotonin in patients without atherosclerosis causes a dose-dependent increase in coronary blood flow. They also observed a dose-dependent increase in epicardial vessel diameter, which was more marked after the intravenous administration of ketanserin and was similar in magnitude to that produced by the intracoronary injection of nitrates. In a similar study in patients without coronary atherosclerosis, we observed small, nonsignificant increases in epicardial diameter at infused doses of 10'-10-i mol/l but constriction most marked in the distal vessels at 10-4 mol/1. This conclusion is consistent with previous observations of isolated human coronary vessels that demonstrate that the constrictor effect of serotonin is mediated by S,-like and S2 receptors, as it is only partially antagonized by ketanserin, a selective S2 receptor antagonist, but completely abolished by methiothepin, an antagonist at S,-like and S2 receptors.9 Furthermore, sumatriptan and 5-carboxamidotryptamine, which are selective S,-like agonists, also constrict isolated human coronary vessels.10,"1,"6
In the control patients and those with stable angina, the constrictor effects of serotonin were more marked in the distal epicardial vessels; however, the inhibitory effects of ketanserin on distal constriction were significant only in the vessel segments from the control patients. The reasons underlying these differences are unclear and cannot be completely defined from the data obtained in the present study. It 
Clinical Implications
The potential therapeutic benefit of serotonin receptor antagonists in unstable angina is based on the assumption that local concentrations of serotonin, released by aggregating platelets in the coronary circulation, are sufficient to evoke detrimental effects, and that serotonin antagonists will prevent these effects. Clinical studies suggest that platelet activation occurs in unstable angina,29 and studies in vitro have shown that when platelets aggregate in numbers equivalent to those circulating in blood, the concentration of serotonin may reach 6 x mol/1.30 The dose of serotonin infused in the present study would, if one allows for dilution by coronary blood flow, produce an effective intracoronary concentration of approximately 10-6 mol/l. The actual concentration in the artery may, however, be less because serotonin is rapidly removed from the bloodstream by active endothelial uptake and by adsorption onto circulating platelets.31 Caution must be advised in the extrapolation of these results, which were obtained during intracoronary infusions of serotonin. However, the demonstration that a functionally important population of S,-like receptors is present on atherosclerotic human epicardial coronary arteries suggests that blockade of S2 receptors alone may not be sufficient to inhibit the vasoconstrictor effects of serotonin in vivo, when serotonin is released after the intracoronary activation of platelets.
